NASHUA, N.H., Nov. 14 /PRNewswire-FirstCall/ -- iCAD, Inc. (Nasdaq:
ICAD), an industry-leading provider of Computer-Aided Detection (CAD)
solutions for the early identification of cancer, today announced it will
unveil its latest CAD innovations for more than 60,000 industry experts
attending the Radiological Society of North America (RSNA)'s Annual Meeting
in Chicago, November 25-30 (booth #3507).
At the meeting, iCAD will provide demonstrations of its SecondLook(R)
suite of products, including its most recent developments that showcase
SecondLook Digital's unique compatibility with industry leading Full-Field
Digital Mammography (FFDM) and Computed Radiography (CR) solutions. iCAD's
latest innovations deliver powerful performance improvements increasing the
radiologist's confidence of findings while enhancing workflow. iCAD will
also feature CAD applications for tomosynthesis and CT colonography that
are currently under development.
"iCAD sees a wide range of application opportunities for CAD, and the
RSNA is the ideal venue to share our vision for the direction of the
technology with key industry leaders. Our expanded and enhanced mammography
solutions coupled with new development areas, such as CT colonography, will
help drive the future of CAD," said Ken Ferry, Chief Executive Officer of
iCAD, Inc. "As facilities look to expand their CAD offerings, iCAD's proven
interoperability makes it an ideal choice for both large and small scale
implementations."
iCAD offers high-performance CAD solutions for both digital and
film-based mammography systems. iCAD's systems are based on sophisticated
algorithms that analyze the data; automatically identifying and marking
suspicious regions in the images. The result is earlier detection of
hard-to-find cancers, improved workflow for radiologists, and higher
quality patient care.
Additionally, iCAD is developing CAD solutions for use with virtual
colonoscopy to improve the detection of colonic polyps. By focusing on
superior identification capabilities, iCAD's system for virtual colonoscopy
is designed to assist in improving accuracy and workflow during the reading
process.
About iCAD, Inc.
iCAD, Inc. (Nasdaq: ICAD) is an industry-leading provider of Computer-
Aided Detection (CAD) solutions that enable healthcare professionals to
better serve patients by identifying pathologies and pinpointing cancer
earlier. iCAD offers a comprehensive range of high-performance, upgradeable
CAD systems for the high, mid and low volume mammography markets. iCAD is
entrusted with the task of early cancer detection by over one thousand
women's healthcare centers worldwide. For more information, call +1 877
iCADnow or visit http://www.icadmed.com.
For iCAD, contact Darlene Deptula-Hicks, EVP and CFO at 603-882-5200 x7944 or
via email at ddeptula@icadmed.com
For iCAD Investor Relations, contact Anne Marie Fields of
Lippert/Heilshorn &
Associates at 212-838-3777 x6604 or via email at icad@lhai.com
For iCAD Public Relations, contact Wendy Ryan of Schwartz Communications
at 781-684-0770 or via email at icad@schwartz-pr.com
"Safe Harbor" Statement under the Private Securities Litigation Reform
Act of 1995:
Certain statements contained in this News Release constitute "forward-
looking statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements involve a number of
known and unknown risks, uncertainties and other factors which may cause
the actual results, performance or achievements of the Company to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Such factors
include, but are not limited to, the risks of uncertainty of patent
protection, the impact of supply and manufacturing constraints or
difficulties, product market acceptance, possible technological
obsolescence, increased competition, customer concentration and other risks
detailed in the Company's filings with the Securities and Exchange
Commission. The words "believe", "demonstrate", "intend", "expect",
"estimate", "anticipate", "likely", and similar expressions identify
forward- looking statements. Readers are cautioned not to place undue
reliance on those forward-looking statements, which speak only as of the
date the statement was made. The Company is under no obligation to provide
any updates to any information contained in this release.
SOURCE iCAD, Inc.
 back to top
Related links:
http://www.icadmed.com
CONTACT:
Darlene Deptula-Hicks, EVP and CFO of iCAD,
Inc., +1-603-882-5200 x7944, ddeptula@icadmed.com, or Investor
Relations, Anne Marie Fields of Lippert, Heilshorn & Associates,
+1-212-838-3777 x6604, icad@lhai.com, or Public Relations, Wendy
Ryan of Schwartz Communications, +1-781-684-0770,
icad@schwartz-pr.com, both for iCAD, Inc.
|
